{"id":"csdmards","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"csDMARDs, or conventional synthetic disease-modifying antirheumatic drugs, are a class of medications that have been used for decades to treat autoimmune diseases like rheumatoid arthritis. They work by suppressing the immune system to reduce inflammation and slow disease progression. This is achieved through various mechanisms, including the inhibition of cytokines and the modulation of immune cell function.","oneSentence":"csDMARDs work by suppressing the immune system to reduce inflammation and slow disease progression in conditions such as rheumatoid arthritis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:58.088Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT07276581","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-15","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT07452445","phase":"PHASE4","title":"Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-03-01","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT06842316","phase":"","title":"Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","status":"RECRUITING","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2025-04-10","conditions":"Inflammatory Disorder of Immune System, Spondylitis, Ankylosing, Arthritis, Rheumatoid","enrollment":100},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT06144567","phase":"","title":"Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2023-12","conditions":"Psoriatic Arthritis","enrollment":19},{"nctId":"NCT04333771","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-31","conditions":"Rheumatoid Arthritis","enrollment":566},{"nctId":"NCT06099535","phase":"PHASE2","title":"A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2021-11-18","conditions":"Rheumatoid Arthritis","enrollment":156},{"nctId":"NCT04134728","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-31","conditions":"Arthritis, Rheumatoid","enrollment":550},{"nctId":"NCT02720523","phase":"PHASE2, PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-22","conditions":"Rheumatoid Arthritis","enrollment":197},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT02675426","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-17","conditions":"Rheumatoid Arthritis","enrollment":661},{"nctId":"NCT02706847","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-15","conditions":"Rheumatoid Arthritis","enrollment":499},{"nctId":"NCT05626348","phase":"PHASE4","title":"The Clinical Efficacy of Immunomodulators in RA Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-12-22","conditions":"Arthritis, Rheumatoid","enrollment":400},{"nctId":"NCT05606107","phase":"PHASE4","title":"To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-05-20","conditions":"Rheumatoid Arthritis","enrollment":230},{"nctId":"NCT05424393","phase":"","title":"Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-04","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT05165771","phase":"PHASE2","title":"Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2022-07","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT05078502","phase":"NA","title":"Role of Vitamin D3 Supplementation With Conventional Synthetic Disease Modifying Antirheumatic Drugs(csDMARD) in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2021-06-01","conditions":"Rheumatoid Arthritis","enrollment":58},{"nctId":"NCT05090410","phase":"PHASE3","title":"Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate","status":"UNKNOWN","sponsor":"Atsushi Kawakami","startDate":"2021-03-03","conditions":"Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor","enrollment":400},{"nctId":"NCT02955212","phase":"PHASE3","title":"A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-01-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":338},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT02608112","phase":"","title":"Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-31","conditions":"Rheumatoid Arthritis","enrollment":291},{"nctId":"NCT04077957","phase":"PHASE4","title":"Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-10-07","conditions":"Ankylosing Spondylitis, Spondyloarthritis","enrollment":100},{"nctId":"NCT02001987","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":139}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":1,"reaction":"DEAFNESS NEUROSENSORY"},{"count":1,"reaction":"PNEUMOTHORAX SPONTANEOUS"},{"count":1,"reaction":"PYELONEPHRITIS ACUTE"},{"count":1,"reaction":"SEPSIS"}],"_approvalHistory":[],"publicationCount":801,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"csDMARDs","genericName":"csDMARDs","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"csDMARDs work by suppressing the immune system to reduce inflammation and slow disease progression in conditions such as rheumatoid arthritis. Used for Rheumatoid arthritis, Psoriatic arthritis, Juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}